Compare Neurocrine Biosciences Inc (NBIX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Viatris Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Neurocrine Biosciences Inc and Viatris Inc are close in size by market cap, and Viatris Inc pays a 2.83% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | VTRS | |
|---|---|---|
Market Cap | $17.40B | $19.79B |
Sector | Health | Health |
52-Week High | $180.55 | $17.39 |
52-Week Low | $123.10 | $8.74 |
Enterprise Value | $16.49B | $32.00B |
Dividend Yield | — | 2.83% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
